Autopsy report · NCT04845191

COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

“The sponsor has changed the development plans which is not for safety reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

ImmunityBio, Inc.

Sponsor type

Industry

Conditions

Covid19

Interventions

hAd5-S-Fusion+N-ETSD vaccine

Participants

0

Trials that died the same way

• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (75% match in meaning)
• Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
  “Sponsor decision; the decision is not related to any safety concern.” (74% match in meaning)
• A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
  “Sponsor decision:Change the Development plan” (73% match in meaning)
• Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
  “Sponsor decision not related to safety concerns” (73% match in meaning)
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  “Sponsor decision not related to safety reasons” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.